Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record.

Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial

Tong, M J, Reddy, K R, Lee, W M, Pockros, P J, Hoefs, J C, Keeffe, E B, Hollinger, F B, Hathcote, E J, White, H, Foust, R T, Jensen, D M, Krawitt, E L, Fromm, H, Black, M, Blatt, L M, Klein, M, Lubina, J · 1997 · Hepatology

Abstract

This multicenter, randomized, controlled, double-blind, phase III study in 704 patients with chronic hepatitis C infection compared treatment with consensus interferon (CIFN), a non-natural recombinant type-1 interferon, with a standard regimen of recombinant interferon alfa-2b (IFN-α2b). Patients were randomized to receive CIFN at doses of 3 μg or 9 μg, or 15 μg IFN-α2b (3 million units), subcutaneously three times weekly for 24 weeks, followed by 24 weeks of observation. Efficacy was assessed by normalization of serum alanine transaminase (ALT) concentration and decrease in serum hepatitis C virus (HCV) RNA concentration below the limit of detection by reverse- transcription polymerase chain reaction (RT-PCR) (100 copies/mL). The beneficial effect of CIFN was greater with the 9-μg dose than the 3- μg dose. The sustained ALT and HCV RNA response rates were 20.3% and 12.1%, respectively, in the 9-μg CIFN cohort and 19.6% and 11.3%, respectively, in the 15-μg IFN-α2b cohort. However, patients receiving 9 μg of CIFN had a greater reduction in serum HCV RNA concentrations compared with patients receiving 15 μg IFN- α2b over the course of treatment (P < .01). Similarly, analysis of patients infected with HCV genotype 1 showed a greater reduction in serum HCV RNA concentration over the course of treatment for the 9- μg CIFN group when compared with the 15-μg IFN-α2b group (P < .01). In addition, a greater percentage of patients infected with HCV genotype 1 treated with 9 μg CIFN had undetectable HCV RNA concentrations when compared with patients in the 15-μg IFN-α2b cohort at the end of treatment (24% vs. 15%; P = .04). Improvements in liver histology were noted in all three treatment groups; 52% to 55% of the patients in the three cohorts had at least a 2-unit improvement in the Knodell score at the end of the posttreatment period. The adverse- events profiles were characteristic of treatment with type-1 interferon, and the incidences of anti-interferon antibody formation did not significantly differ among the three treatment groups. These results show that administration of 9 μg CIFN three times weekly for 6 months is safe and is effective in reducing serum HCV RNA concentration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.510260330

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 179

Metadata

Authors
Tong, M. J., Reddy, K. R., Lee, W. M., Pockros, P. J., Hoefs, J. C., Keeffe, E. B., Hollinger, F. B., Hathcote, E. J., White, H., Foust, R. T., Jensen, D. M., Krawitt, E. L., Fromm, H., Black, M., Blatt, L. M., Klein, M., & Lubina, J.
Venue
Hepatology
Published
1997-09
Volume
26
Issue
3
Pages
747-754
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2105965047
Cited by
179
References
0
FWCI
11.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial. https://app.cochat.ai/papers/10.1002/hep.510260330
The paper
Tong, M. J., Reddy, K. R., Lee, W. M., Pockros, P. J., Hoefs, J. C., Keeffe, E. B., Hollinger, F. B., Hathcote, E. J., White, H., Foust, R. T., Jensen, D. M., Krawitt, E. L., Fromm, H., Black, M., Blatt, L. M., Klein, M., & Lubina, J. (1997). Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial. Hepatology. https://doi.org/10.1002/hep.510260330

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.